RSSDI Repository, Complications of Diabetes Demonstration
RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

Advanced Search
  • Home/
  • Article /
  • Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes.

Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes.

Add to Collection
2022 Dec Others R Jain, N Bhavatharini, T Saravanan, V Seshiah… - Cureus, 2022 - cureus.com

Full Author : ['Jain, Rajesh', 'Bhavatharini, Natrajan', 'Saravanan, Thangavel', 'Seshiah, Veeraswamy', 'Jain, Nishchal 3rd']
Journal Title : Cureus
Chapter : Section4
Journal Year : 2022

The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no sign..... Read More

Keywords : ['sodiumglucose transport protein inhibitor remogliflozin', 'acute kidney injury', 'use', 'possibility', 'diabetes']
PubMed Link : https://www.cureus.com/articles/127035-use-of-sodium-glucose-transport-protein-2-sglt2-inhibitor-remogliflozin-and-possibility-of-acute-kidney-injury-in-type-2-diabetes.pdf